You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery

Version: N/A ID: GL 17-12 sep 2019
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
R. Auer, D. Sivajohanathan, J. Biagi, J. Conner, E. Kennedy, T. May, the HIPEC Guideline Group

Guideline Objective

To determine evidence-based indications for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).

Patient Population

Adults (≥18 years old) with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian, or primary peritoneal carcinoma.

Intended Guideline Users

This guideline is intended for clinicians involved in the care of patients with mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian, or primary peritoneal carcinoma.

Research Questions

  1. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with ovarian cancer? If so, which patients derive greater benefit?
  2. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with peritoneal colorectal carcinomatosis? If so, which patients derive greater benefit?
  3. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with gastric peritoneal carcinomatosis ? If so, which patients derive greater benefit?
  4. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with peritoneal mesothelioma? If so, which patients derive greater benefit?
  5. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with disseminated mucinous neoplasm of the appendix? If so, which patients derive greater benefit?
pdf download Summary (PDF) (147.83 Ko)
pdf download Full Report (PDF) (1.05 Mo)